LyGenesis is a clinical-stage cell therapy company that utilizes a patient's lymph nodes as bioreactors to grow functioning ectopic organs, addressing the shortage of available organs for transplantation. Their technology allows one donated liver to potentially treat multiple patients with end-stage liver disease through a minimally invasive outpatient procedure.
Funding
$37.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PMFounders
Product
Problem
There is a critical shortage of available organs for transplantation, leaving many patients with end-stage organ diseases without access to life-saving treatments. Traditional organ transplantation faces challenges related to donor availability, surgical complexity, and associated medical risks.
Solution
LyGenesis is developing cell therapies that use a patient's own lymph nodes as bioreactors to grow functioning ectopic organs, addressing the organ shortage. Their technology allows a single donor liver to potentially treat multiple patients with end-stage liver disease (ESLD). The cell therapy is delivered via a minimally invasive outpatient endoscopic ultrasound procedure, which is designed to reduce medical risks and costs compared to full organ transplantation. The allogeneic cell therapies leverage the biology of the lymph node to engraft, proliferate, and form functional ectopic organs that replicate the native organ's function.
Target Audience
The primary target audience includes patients with end-stage liver disease, type 1 diabetes, end-stage renal disease, and conditions associated with aging, as well as the healthcare providers who treat them.
Features
- Utilizes patient's lymph nodes as bioreactors for growing ectopic organs.
- Minimally invasive outpatient endoscopic ultrasound procedure for cell therapy delivery.
- Allogeneic cell therapies designed to engraft, proliferate, and form functional ectopic organs.
- Potential to treat multiple ESLD patients from a single donor liver.
- Pipeline includes cell therapies for liver, thymus, kidney, and pancreas regeneration.